A phase 3 randomized study (HOMER) of ofatumumab vs rituximab in iNHL relapsed after rituximab-containing therapy

Because of high relapse rates with rituximab combinations, there is an unmet need for new therapeutic agents for treatment of indolent B-cell non-Hodgkin lymphoma (iNHL) or follicular lymphoma (FL). In previous trials, ofatumumab in combination with chemotherapy showed good results in relapsed/refra...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Maloney, David G., Ogura, Michinori, Fukuhara, Noriko, Davis, Jaclyn, Lasher, Janet, Izquierdo, Miguel, Banerjee, Hiya, Tobinai, Kensei
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2020
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7448588/
https://ncbi.nlm.nih.gov/pubmed/32810220
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020001942
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados